Boston Scientific Agrees To Pay $4.2Bn For UK Interventional Oncology Firm BTG
A busy year of M&A for Boston Scientific just got busier with a $4.2bn cash offer for UK interventional medicine specialist BTG. Completion is expected by mid-year 2019.
You may also be interested in...
After a record year for medtech M&A deal-making in 2018, Medtech Insight investigates how activity may unfold in the coming year and some of the biggest trends that could hit the industry.
Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, but BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings.